Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in Kentucky?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes, but Kentucky's Board of Pharmacy has been unusually explicit about GLP-1 copies. A Kentucky resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Kentucky-licensed provider, including by telehealth, which KRS 211.332 defines to include synchronous and asynchronous technology. Kentucky law does not settle whether a first prescription can be issued without a live visit, and KRS 311.597 says an on-line evaluation by questionnaire is not enough. Compounded peptides are available only when eligible under federal 503A rules and dispensed by a Kentucky-permitted pharmacy; Kentucky Board of Pharmacy regulation 201 KAR 2:076 separately prohibits compounding essential copies of commercially available drugs, and the Board's 2025 guidance states that pharmacies in general may not compound semaglutide or tirzepatide.

Regulatory: Telehealth allowedRegulatory: Async unclearRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous unclear; a questionnaire alone is not enough
Compounded GLP-1
Limited

Can a Kentucky resident get peptides by telehealth?

Kentucky defines telehealth in KRS 211.332(5) to include synchronous and asynchronous technology, remote patient monitoring, and audio-only encounters, and excludes care delivered by electronic mail, text, chat, or fax unless a state agency allows it; 900 KAR 12:005, Section 2(7) lists asynchronous store-and-forward technology and secure clinical text chat among the modalities providers may use. KRS 211.336 bars state agencies from requiring a provider to be physically present with the patient unless the provider decides that is medically necessary. KRS 311.5975 requires physicians using telehealth to obtain informed consent and protect confidentiality. KRS 311.597(1)(e) makes it unprofessional conduct to prescribe in response to an electronic communication without verifying the patient's identity, establishing a documented diagnosis, and keeping a current medical record, and says an electronic, on-line, or telephonic evaluation by questionnaire is inadequate for the initial evaluation or any follow-up. The Board of Medical Licensure's opinion on telemedicine (amended September 15, 2022; guidance without the force of law) says a physician-patient relationship may be established using telemedicine technologies if the standard of care is met and that prescribing based solely on static online questionnaires is not acceptable. Physicians must hold a Kentucky license (Kentucky participates in the Interstate Medical Licensure Compact). This record leaves asynchronous prescribing unknown because the law is ambiguous: asynchronous technology is recognized as telehealth and no real-time visit is required by name, but no provision says an asynchronous evaluation is enough for a first prescription, and the statute rules out an on-line evaluation by questionnaire. [2] [5] [6] [7] [8] [9] [10] [19]

How does the Kentucky pharmacy board treat compounding?

Compounding regulator for Kentucky
BoardKentucky Board of Pharmacy
Eligible substancesFollows the federal 503A framework

The Kentucky Board of Pharmacy regulates pharmacies under KRS chapter 315 and Title 201, chapter 2 of the Kentucky Administrative Regulations. Kentucky follows the federal 503A framework for which bulk substances may be compounded, and 201 KAR 2:076 (compounding) incorporates the federal essentially-a-copy limit into state law by prohibiting compounding of essential copies of a commercially available drug product unless authorized by 21 U.S.C. 353a, which the Board says it enforces against every Kentucky licensee and permit holder. Out-of-state pharmacies that ship dispensed drugs to Kentucky patients must hold a Kentucky out-of-state pharmacy permit. KRS 315.0351 requires every pharmacy outside Kentucky that does business in the state, physically or by internet, phone, mail, or other means, to hold an out-of-state pharmacy permit from the Board, disclose its principal officers and dispensing pharmacists annually, keep its home-state license valid, and file its most recent home-state inspection report before applying and each later report after. [1] [3] [4] [11] [14]

Can you get compounded GLP-1s in Kentucky?

Regulatory: Compounded GLP-1 limited

The Kentucky Board of Pharmacy's 2025 guidance, "Important Update: Compounding Semaglutide and Tirzepatide," states that in general compounding pharmacies may not compound semaglutide or tirzepatide because they are commercially available, that adding another ingredient such as B12 does not avoid the essentially-a-copy rule, that a lower price is not a valid reason, and that noncompliant compounding may lead to action by both FDA and the Board. The narrow exceptions are a documented patient-specific change that produces a significant difference for that patient, or a return of the drug to the FDA shortage list. [3] [4] [17]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Kentucky?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in Kentucky

What you'll actually find in Kentucky, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [22] [23] [24]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [25]

What Kentucky has done

PeptideAgent has not found a board or legislative action on peptides in Kentucky.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [27] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [28] [29] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in Kentucky. The state law we checked does not settle whether a prescription can be issued without a live visit, so expect one. State law says an online questionnaire alone is not enough. [2] [5] [6] [7] [8] [9] [10] [19] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Kentucky Board of Pharmacy; its license search: FDA BeSafeRx: state board of pharmacy license lookups. [26]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [25]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [15] [30] [31]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [26] [32] [33]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [24] [33] [34]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [25] [35] [36] [37] [38] [39]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [25]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [26]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [24]
  • Pharmacy: Is this made for me on a prescription written in my name? [34]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [24] [33]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [24]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in Kentucky?

Only Kentucky-permitted pharmacies may dispense prescription drugs to Kentucky patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and fall outside Kentucky's compounding regulation. The Kentucky Food, Drug and Cosmetic Act, KRS 217.075, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has become effective under the federal act; its investigational exemption covers only drugs intended solely for investigational use by qualified experts and labeled for investigational use only. [1] [12] [18]

Peptide-specific notes for Kentucky

Peptide-specific notes for Kentucky
PeptideNote
SemaglutideAvailable branded by prescription, including by telehealth. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies in general may not compound semaglutide, and 201 KAR 2:076 makes the essentially-a-copy prohibition enforceable by the Board; adding B12 does not change that. [3] [4]
TirzepatideAvailable branded by prescription. The same Kentucky guidance covers tirzepatide: 503A compounding under the shortage allowance ended in 2025, and compounded copies are allowed only for a documented significant patient-specific difference. [3] [17]
BPC-157Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). Because it is not commercially available, the essentially-a-copy rule does not apply to it; Kentucky pharmacies apply the federal bulks eligibility test. [4] [15] [16] [20] [21]

Compare: Wegovy vs Zepbound.

Frequently asked questions

Can Kentucky pharmacies compound semaglutide or tirzepatide?

In general, no. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies may not compound semaglutide or tirzepatide because both are commercially available, and 201 KAR 2:076 lets the Board enforce the federal essentially-a-copy ban. The exceptions are a documented patient-specific change that makes a significant difference for that patient, or a return to the FDA shortage list. [3] [4]

Does adding B12 to compounded semaglutide make it legal in Kentucky?

No. The Kentucky Board's guidance repeats FDA's position that a compounded product containing the same active ingredients as commercially available drugs, such as semaglutide plus B12, is still essentially a copy unless the prescriber documents a patient-specific need. [3]

Do I need an in-person visit to get a prescription by telehealth in Kentucky?

Not necessarily. KRS 211.336 bars state agencies that write telehealth regulations from requiring a provider to be physically present with the patient unless the provider decides it is medically necessary. The Board of Medical Licensure's telemedicine opinion, which is guidance without the force of law, says a physician-patient relationship may be established using telemedicine technologies if the standard of care is met. Kentucky law does not settle whether a visit with no live contact is enough for a first prescription. KRS 311.597 says an electronic, on-line, or telephonic evaluation by questionnaire is inadequate. The prescriber must be licensed in Kentucky. [6] [8] [9] [10]

What does an out-of-state pharmacy need to ship compounded peptides to Kentucky?

A Kentucky out-of-state pharmacy permit from the Kentucky Board of Pharmacy, and any compounded product must still comply with 201 KAR 2:076. Check the Board's license verification before ordering. [1] [4] [11]

Can a Kentucky pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Kentucky follows the federal 503A framework for which bulk substances may be compounded. [15] [16] [20] [21]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]Kentucky Board of Pharmacy
  2. [2]Kentucky Board of Medical Licensure
  3. [3]Kentucky Board of Pharmacy: Important update, compounding semaglutide and tirzepatide (2025)2025
  4. [4]201 KAR 2:076, Compounding (Kentucky Board of Pharmacy)
  5. [5]KRS 211.332, Definitions for KRS 211.332 to 211.338 (telehealth) (Kentucky Legislative Research Commission)
  6. [6]KRS 211.336, Duties of agency promulgating administrative regulations relating to telehealth (Kentucky Legislative Research Commission)
  7. [7]900 KAR 12:005, Telehealth terminology and requirements
  8. [8]KRS 311.5975, Duty of treating physician utilizing telehealth (Kentucky Legislative Research Commission)
  9. [9]KRS 311.597, Acts declared to constitute dishonorable, unethical, or unprofessional conduct (Kentucky Legislative Research Commission)
  10. [10]Kentucky Board of Medical Licensure: Board Opinion Regarding the Use of Telemedicine Technologies in the Practice of Medicine (amended September 15, 2022)

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in Kentucky?. https://peptideagent.ai/legal/kentucky
HTML link
<a href="https://peptideagent.ai/legal/kentucky">Are peptides legal in Kentucky?</a>, PeptideAgent, updated October 28, 2026.